Massive news today, as members of the United Commission on Narcotic Drugs has received recommendations by the WHO to reschedule Cannabis.
On CBD, the committee noted:
“Cannabidiol is found in cannabis and cannabis resin but does not have psychoactive properties and has no potential for abuse and no potential to produce dependence. It does not have significant ill-effects. Cannabidiol has been shown to be effective in the management of certain treatment-resistant, childhood-onset epilepsy disorders. It was approved for this use in the United States in 2018 and is currently under consideration for approval by the EU.”
However, doubts remains about products containing both THC & CBD
“The Committee recommended that a footnote be added to Schedule I of the 1961 Single Convention on Narcotic Drugs to read: ‘Preparations containing predominantly cannabidiol and not more than 0.2% of delta-9-tetrahydrocannabinol are not under international control.'”
Read the full article here